Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 1.00 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | POLG | P54098 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclic Cidofovir SCHEMBL14461986 | 1.00 | FGFR1 (1.00) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| Cyclic Cidofovir SCHEMBL2380283 | 1.00 | FGFR1 (1.00) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL13825656 | 0.86 | FGFR1 (0.75) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL10047653 | 0.85 | FGFR1 (0.74) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL13799135 | 0.85 | FGFR1 (0.74) | FGFR1HPRT1 | |
| SCHEMBL13799138 | 0.85 | FGFR1 (0.74) | FGFR1HPRT1 | |
| SCHEMBL27292735 | 0.83 | FGFR1 (0.69) | FGFR1LMNAPDE3ACACNA1FALB | |
| SCHEMBL14308878 | 0.82 | FGFR1 (0.71) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL13819331 | 0.82 | FGFR1 (0.70) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL10047660 | 0.82 | FGFR1 (0.69) | FGFR1HPRT1LMNAPDE3ACACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2025-06-26 | — | — | US | claimed |
| EP-3147611-B1 | METHOD AND SYSTEM FOR SEPARATING CARBON DIOXIDE FROM FLUE GAS | GENERAL ELECTRIC TECHNOLOGY GMBH (CH) | 2024-07-17 | — | — | EP | claimed |
| CN-115314609-B | Automatic acquisition method and device for fire hole video of aluminum electrolysis cell | 中南大学 | 2023-11-28 | — | — | CN | claimed |
| CN-115314609-A | Automatic acquisition method and device for aluminum electrolysis cell fire hole video | 中南大学 | 2022-11-08 | — | — | CN | claimed |
| EP-3384907-B1 | ORAL VETERINARY COMPOSITION WITH GABAPENTIN | CHAIT AUERBACH JAIME SAMUEL (MX) | 2026-03-25 | — | — | EP | disclosed |
| US-20260073869-A1 | DISPLAY DEVICE | JAPAN DISPLAY INC (JP) | 2026-03-12 | — | — | US | disclosed |
| US-12397058-B2 | Metabolically stable prodrugs | TSRL, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2025-06-26 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024259930-A9 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-12283236-B2 | Processor for compensate image and operation method thereof | NOVATEK MICROELECTRONICS CORP. (TW) | 2025-04-22 | — | — | US | disclosed |
| CN-119854361-A | Internet of things block chain slicing method and device | 北京邮电大学 | 2025-04-18 | — | — | CN | disclosed |
| WO-2007130783-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| EP-0874858-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5756486-A | CYCLIZED NUCLEOTIDE; VIRICIDE | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5717095-A | PHOSPHONATES CYTOSINE COMPOUND | GILEAD SCIENCES, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997024361-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5591851-A | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | ATIC, PIGS, TYMP | FGFR1 1493/4885HPRT1 478/4885LMNA 1007/4885 |
| US-20260073869-A1 | DISPLAY DEVICE | NECTIN4, EPHA4, L1CAM | FGFR1 2616/4885HPRT1 3474/4885LMNA 3271/4885 |
| US-12397058-B2 | Metabolically stable prodrugs | CES1, CES2, CYP2S1 | FGFR1 1170/4885HPRT1 387/4885LMNA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.